Spanish biotechnology firm Aelix Therapeutics has commenced patient enrolment in a Phase I clinical trial (AELIX-002) of HTI vaccine to treat patients infected with HIV.

Designed by the firm’s chief scientific officer Dr Christian Brander and colleagues, HTI vaccine immunogen combines specific HIV regions that are enriched with T-cell responses in individuals who can control the virus without antiretroviral drugs.

The randomised, double-blind, placebo-controlled Phase I AELIX-002 will evaluate the safety, tolerability and immunogenicity of the vaccine.

Read the full article here